NexgenRx Yönetim

Yönetim kriter kontrolleri 2/4

NexgenRx CEO'su Ron Loucks, Mar2003 tarihinde atandı, in görev süresi 21.67 yıldır. in toplam yıllık tazminatı CA$ 313.34K olup, şirket hissesi ve opsiyonları dahil olmak üzere 75% maaş ve 25% ikramiyelerden oluşmaktadır. şirketin hisselerinin 10.48% ine doğrudan sahiptir ve bu hisseler CA$ 2.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 12.5 yıldır.

Anahtar bilgiler

Ron Loucks

İcra Kurulu Başkanı

CA$313.3k

Toplam tazminat

CEO maaş yüzdesi	75.0%
CEO görev süresi	21.7yrs
CEO sahipliği	10.5%
Yönetim ortalama görev süresi	5.5yrs
Yönetim Kurulu ortalama görev süresi	12.5yrs

Son yönetim güncellemeleri

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

CEO Tazminat Analizi

Ron Loucks'un ücretlendirmesi NexgenRx'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$25k
Mar 31 2024	n/a	n/a	-CA$66k
Dec 31 2023	CA$313k	CA$235k	-CA$332k
Sep 30 2023	n/a	n/a	-CA$310k
Jun 30 2023	n/a	n/a	-CA$244k
Mar 31 2023	n/a	n/a	-CA$172k
Dec 31 2022	CA$287k	CA$235k	-CA$22k
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$4m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	CA$230k	CA$215k	CA$4m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$2m
Mar 31 2021	n/a	n/a	CA$2m
Dec 31 2020	CA$153k	CA$140k	CA$2m
Sep 30 2020	n/a	n/a	CA$1m
Jun 30 2020	n/a	n/a	CA$483k
Mar 31 2020	n/a	n/a	-CA$31k
Dec 31 2019	CA$181k	CA$165k	-CA$208k
Sep 30 2019	n/a	n/a	CA$38k
Jun 30 2019	n/a	n/a	-CA$147k
Mar 31 2019	n/a	n/a	-CA$438k
Dec 31 2018	CA$181k	CA$165k	-CA$697k
Sep 30 2018	n/a	n/a	-CA$1m
Jun 30 2018	n/a	n/a	-CA$1m
Mar 31 2018	n/a	n/a	-CA$793k
Dec 31 2017	CA$181k	CA$165k	-CA$626k

Tazminat ve Piyasa: Ron 'nin toplam tazminatı ($USD 222.40K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 170.34K ).

Tazminat ve Kazançlar: Ron şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Ron Loucks (74 yo)

21.7yrs

Görev süresi

CA$313,342

Tazminat

Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Kelly Elher	Chief Financial Officer	7.5yrs	CA$60.00k	0.63% CA$ 132.5k
Andrew Munroe	Vice President of Operations	less than a year	CA$169.40k	Veri yok
Jason Robinson	Vice President of Administration	no data	Veri yok	Veri yok
Doreen Harvey	Lead Human Resources	no data	Veri yok	Veri yok
Paul Bolger	Company Secretary	3.4yrs	Veri yok	Veri yok
Avik Debroy	Financial Controller	no data	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NXG 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Thomas Corcoran	Independent Chairman	18.7yrs	CA$30.00k	0.88% CA$ 184.5k
Linda Brennan	Director	less than a year	Veri yok	Veri yok
Randolf McGlynn	Independent Director	6.3yrs	CA$20.00k	0.14% CA$ 29.5k

12.5yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NXG 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.5 yıldır).

NexgenRx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

Recent updates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023)

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş